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Background
Anti-tumor immune response in lung cancer patients
may be evoked by intra-tumoral (IT) administration of
autologous dendritic cells (DC), transduced with a repli-
cation-deficient adenoviral (Ad) vector to express the
secondary lymphoid chemokine (SLC/CCL21) gene.
Here, we evaluated tumor specific immune response
after CCL21 gene-modified DC (Ad-CCL21-DC) admin-
istration in the context of tumor PD-L1 expression.
Methods
Phase I, non-randomized, dose escalating, multi-cohort
trial was conducted to enroll patients with Stage IIIB/IV
NSCLC. Sixteen patients received 2 vaccinations at a dose
of Ad-CCL21-DC (A, B, C, or D; 1 × 106, 5 × 106, 1 × 107,
or 3 × 107 cells/injection) by IT injection (days 0 and 7).
Peripheral blood was collected for antigen-specific ELI-
SPOT assays, and CT guided needle biopsies of the
primary lung cancer were obtained for PD-L1 expression
by real time PCR and evaluation of cellular infiltrates by
immunohistochemistry.
Results
Peripheral blood of 16 subjects was evaluated by ELISPOT
assays. Positive response was defined as 2-fold increase in
number of spots above background with an absolute num-
ber of >20 spots/2 × 105 cells (positive responder; PR). A
mixed response was defined as a positive response with
high IFN-g background expression at day 0 compared to
post-vaccine time points (mixed responder; MR). There
were 19% (3/16) PR and 19% (3/16) MR for a total of 38%
(6/16) total responders. The average PD-L1 gene copy
number was 1344 (non-responder; NR) compared to 394
(MR), and 684 (PR) on day 7. Tumor CD8 T cell infiltra-
tion was induced in 40% (6/15; all subjects), 33% (3/9;
NR), and 50% (3/6; MR & PR).
Conclusion
Intra-tumoral administration of autologous dendritic
cells expressing the SLC/CCL21 gene demonstrated that
1) anti-tumor specific immune responses are elicited
and correlate with lower PD-L1 expression, and 2) CD8
T cell infiltration into the tumor is induced.
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